Business
US-HEALTH-VAPING-JUUL
Juul Labs Inc. vaping e-cigarettes (Patrick T. Fallon/Getty Images)
Weird Money

Four-figure Juul settlements are the hot new social-media trend

As part of a $200 million+ settlement, Juul has been Venmoing former customers thousands of dollars.

Jack Raines

While researching (read: scrolling through X mindlessly) yesterday, I came across some interesting screenshots showing that folks were receiving four-figure Venmo payments from “Juul Labs, Inc. Settlement Administrator.”

A class-action lawsuit was filed against Juul and tobacco company Altria, which bought 35% of Juul Labs for $12.8 billion in 2018, with the plaintiffs alleging that Altria and Juul had led consumers to overpay for Juul products by misleading them about the products’ addictiveness and safety, and that Juul products were unlawfully marketed to minors.

In 2022, Juul agreed to a $245 million settlement, and earlier in 2024, Altria agreed to a $45 million settlement. After fees and taxes, this worked out to $201.9 million being paid out to verified claimants, and on October 18, 2024, those payments started to be distributed, hence the screenshots I saw floating around social media.

According to the BBC, 14 million people tried to claim a share of the settlement, but ultimately, about 842,000 claims were officially validated, averaging out to a ~$240 payout per person. However, as you can see from the screenshots, many of these settlements are more than a magnitude greater than $240, so I decided to look into how exactly this settlement worked. The details are just fantastic.

First, claimants had to submit proofs of purchase, which included date of birth, month and year of a claimant’s first Juul purchase, their frequency of purchase, proof of identification, payment information, and, for claims over $300, proof of purchase via receipts. Claimants who were approved were then allocated “points” based on their age and the years in which they made their purchases, and the total settlement would be distributed pro rata based on claimants’ points.

Claimants who purchased between 2019 and 2022 would get one point, claimants who purchased between 2015 and 2018 would get two points, and “Youth Purchases,” which meant any made by an individual whose first purchase occurred before their 18th birthday, were worth four points.

So if you were a 17-year-old in 2016 who bought, and consequently got hooked on, Juuls, and you continued to buy said Juuls through college, all of your purchases got a 4x point multiplier. Not bad! Unfortunately, there were a few factors that limited the total payouts one could receive:

First, “no Retail Expenditure used to assign Points may exceed $1600 per year,” and second, there was a payment cap for claimants equal to 150% of eligible retail expenditures, or 300% of expenditures in the case of Youth Purchases. However, the largest hypothetical payout from this settlement is still pretty good.

Using the settlement’s class-payment cap, if a 17-year-old in 2015 bought at least $1,600 of Juuls and Juul accessories, and proceeded to do so every year through age 24 in 2022, they could, hypothetically, receive $38,400 (300% times $1,600 per year for eight years). It’s unlikely that anyone received that amount, given that expenditures used to assign points couldn’t exceed $1,600 per year, and the distributions were paid out pro rata based on points, but it is possible.

The logic behind this settlement fascinates me. As someone who was in college between the years of 2015 and 2019, I had plenty of friends (not me) whod bought Juuls, and not a single one of them was shocked to find out that Juul may have been less healthy than advertised. They were smoking flavored nicotine from a battery-powered Wii remote. Also, the rationale that someone who bought a Juul in 2015 at age 17 would still be eligible for a 4x higher distribution on their purchases from 2022 at age 24 is fantastic, too.

Still, I wish the class-payment cap didn’t exist, so we could see how large some of these distributions would have been. In our social-media age where dopamine is more valuable than gold, folks all over TikTok and X are chasing engagement by showing off their $3,000 Juul Venmo payments. You have to think that, somewhere, an upper-class 17-year-old in 2015 with access to an Amex black card was dropping $20,000+ on Juuls every year, and I would love to see the viral TikTok of a Juul settlement whale sharing their $200,000+ Juul payout for social-media clout.

For now, it looks like we’ll have to settle for (no pun intended) the $3,000 TikTok reaction videos.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.